论文部分内容阅读
对９０例乳腺癌、胃癌和大肠癌同时检测癌肿内及转移淋巴结的ｃ－ｅｒｂＢ－２、ｐ５３、ｐ２１的过度表达。结果显示乳腺癌、胃癌和大肠癌转移淋巴中ｃ－ｅｒｂＢ－２、ｐ５３及ｐ２１的阳性率分别与原发癌肿内的阳性率之间无显著性差异（Ｐ＞０．０５）。转移淋巴结与原发癌肿之间ｃ－ｅｒｂＢ－２、ｐ５３及ｐ２１过度表达与否的平均符合率分别为７３．１％、６５．４％、７３．１％。显示转移淋巴结中基因过度表达与否同原发癌肿基本一致。在原发癌肿内ｃ－ｅｒｂＢ－２、ｐ５３及ｐ２１基因的过度表达（除乳腺癌中的ｐ２１表达）分别与癌肿的预后有一定关系，但在不同癌肿中所表示的预后指标有较大差异。９０例中多种基因蛋白过度表达占５２．２％，且提示上述癌肿预后较差。同时检测ｃ－ｅｒｂＢ－２、ｐ５３和ｐ２１过度表达对癌肿的预后判断明显优于单个基因蛋白的检测。
Ninety cases of breast cancer, gastric cancer and colorectal cancer were examined for the over-expression of c-erbB-2, p53 and p21 in cancerous and metastatic lymph nodes. The results showed that the positive rates of c-erbB-2, p53, and p21 in metastatic lymph nodes of breast cancer, gastric cancer, and colorectal cancer were not significantly different from those in primary cancer (P>0.05). The average coincidence rates of c-erbB-2, p53, and p21 overexpression between metastatic lymph nodes and primary cancers were 73.1%, 65.4%, and 73.1%, respectively. It was shown that gene overexpression in metastatic lymph nodes was basically the same as primary cancer. The overexpression of c-erbB-2, p53, and p21 genes (except p21 in breast cancer) is related to the prognosis of cancer in the primary cancer, but the prognostic indicators expressed in different cancers are Big difference. Overexpression of multiple gene proteins accounted for 52.2% in 90 cases, and suggested that the above cancer prognosis is poor. Simultaneous detection of c-erbB-2, p53, and p21 overexpression was significantly superior to the detection of single gene protein in the prognosis of cancer.